10,272,150, which is a continuation of U.S. 28, 2020, which is a continuation of U.S.Īpplication Ser. The method of claim 157, wherein the ionizable cationic lipid The open reading frame of the mRNA has a 1-methylpseudouridineġ58. The method of claim 155, wherein at least 80% of the uracil in Is Compound 25, the neutral lipid is DSPC, the sterol isĬholesterol, and the PEG-modified lipid is PEG-DMG.ġ57. The method of claim 155, wherein the ionizable cationic lipid The method of claim 154, wherein the open reading frameġ56. Wherein the lipid nanoparticle comprises 20-60 mol % ionizableĬationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol,ġ55. Immune response to the BetaCoV S protein or S protein subunit, Nanoparticle in an effective amount to induce in the subject an Reading frame encoding a BetaCoV S protein or S protein subunit, aģ' untranslated region, and a poly(A) tail formulated in a lipid A method comprising administering to a subject an mRNAĬomprising a 5' cap analog, a 5' untranslated region, an open The method of claim 149, wherein the neutral lipid isġ,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), the sterol isĬholesterol, and the PEG-modified lipid isġ,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000ġ54. The method of claim 149, wherein the ionizable cationic lipidġ53. Lipid, 38.5 mol % cholesterol, and 1.5 mol % PEG-modifiedġ52. The method of claim 150, wherein the lipid nanoparticleĬomprises 50 mol % ionizable cationic lipid, 10 mol % neutral Lipid, 25-55 mol % cholesterol, and 0.5-15 mol % polyethyleneġ51. The method of claim 149, wherein the lipid nanoparticleĬomprises 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral The method of claim 136, wherein the lipid nanoparticleĬomprises an ionizable cationic lipid, a neutral lipid, aġ50. The open reading frame of the mRNA has a chemical modification.ġ49. The method of claim 146, wherein at least 80% of the uracil in The method of claim 146, wherein the chemical modification isĪ 1-methylpseudouridine modification or a 1-ethylpseudouridineġ48. The method of claim 136, wherein the mRNA comprises a chemicalġ47. The method of claim 144, wherein the 5' cap analog isġ46. The method of claim 136, wherein the mRNA further comprises aġ45. The method of claim 136, wherein the mRNA further comprises aġ44. The method of claim 136, wherein the mRNA further comprises aĥ' untranslated region and a 3' untranslated region.ġ43. Lipid nanoparticle is administered intramuscularly.ġ42. The method of claim 136, wherein the mRNA formulated in a Neutralizing antibody response specific to the BetaCoV S proteinġ41. The method of claim 139, wherein the immune response is a The method of claim 136, wherein the open reading frameĮncodes a BetaCoV S protein subunit selected from an S1 subunit andġ40. Neutralizing antibody response specific to the BetaCoV Sġ39. The method of claim 137, wherein the immune response is a The method of claim 136, wherein the open reading frameġ38.
Subject an immune response to the Betacoronavirus S protein or Sġ37. In a lipid nanoparticle in an effective amount to induce in the
Ribonucleic acid (mRNA) comprising an open reading frame encoding aīetacoronavirus (BetaCoV) S protein or S protein subunit formulated
A method comprising administering to a subject a messenger Using the vaccines and compositions comprising the vaccines. (RNA) vaccines and combination vaccines, as well as methods of The disclosure relates to respiratory virus ribonucleic acid Invention is credited to Giuseppe Ciaramella, Sunny Himansu. The applicant listed for this patent is ModernaTX, Inc. This patent application is currently assigned to ModernaTX, Inc. patent application number 16/880829 was filed with the patent office on for betacoronavirus mrna vaccine.
0 kommentar(er)
